Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 11/20 | 0.55 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111678 | 0.84 | FBP1 (0.58) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL15094227 | 0.83 | PIN1 (0.45) | FBP1TSHRPIN1MMP8ALDH1A1 | |
| SCHEMBL12670823 | 0.83 | FBP1 (0.56) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL4685610 | 0.82 | FBP1 (0.53) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL9034864 | 0.82 | PPARA (0.49) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL4423002 | 0.81 | PPARA (0.59) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL14092161 | 0.81 | FBP1 (0.55) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL4681650 | 0.80 | FBP1 (0.54) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL31745119 | 0.80 | FBP1 (0.54) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL7981279 | 0.80 | FBP1 (0.54) | FBP1PPARATSHRABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| WO-2005080354-A1 | 1,2,4-TRIAZINES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | FBP1 2382/4885PPARA 1045/4885TSHR 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.